This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Stocks in play: Eupraxia Pharmaceuticals Inc.

Baystreet.ca - Baystreet - Tue Mar 17, 7:43AM CDT

Announced positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc. shares T.EPRX are trading unchanged at $10.13.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).